eu medical research funding

About the programme

EU4Health is the EU’s response to COVID-19's impact on medical and healthcare staff, patients and health systems in Europe. The new programme will go beyond crisis response to pave the way for a stronger, healthier and more resilient Health Union. EU4Health is the largest health programme ever and will invest over €5 billion over seven years (2021-2027) to improve health in the Union.

The programme aims to

• improve and foster health in the Union
• protect people in the Union from serious cross-border threats to health
• improve medicinal products, medical devices and crisis-relevant products
• strengthen health systems

Eligibility: 

• a Member State or an overseas country or territory linked to it
• a third country associated with the Programme or a third country listed in the annual work programme
• a legal entity created under Union law or an international organisation

Some exceptions might apply.

Programme website

Funding opportunities

Open and upcoming calls for proposal under EU4Health.

Open and upcoming calls for tender related to EU4Health.

Budget and performance

Includes performance highlights, key performance indicators, and the performance framework and assessment.

Programme performance webpage

Programme features

Health and Food Safety

3rd Health programme

Direct and indirect management

Cohesion, Resilience and Values

Recovery and Resilience

No target set in the legal basis  ( ℹ )

5.75 billion ( ℹ )  (current prices)

Regulation (EU) 2021/522 of the European Parliament and of the Council .

European Health and Digital Executive Agency (HaDEA)

Related links

Share this page

• Apply for funding Why apply Future opportunities Open calls Closed calls Find partners Call documents
• Shape our future research How call topics are generated Propose ideas Become a contributing partner
• Projects and results Project factsheets Maps and Statistics Health spotlights
• Resources for projects Engaging with regulators Exploitation of project results Open science Project communications Project dissemination Project documents
• News & events News Events Newsletter
• About IHI Mission and objectives Research and innovation agenda IHI funding model Who we are Impact History From IMI to IHI Plans, reports and finances

Innovative Health Initiative

Bold collaborations, transforming health

We are an EU public-private partnership funding health research and innovation. By leveraging the skills of a range of scientific fields - from pharmaceuticals and biotechnology to medical technology and big data - we fund projects that will address public health needs, improve patients' lives, and boost the competitiveness of Europe's health industries.

EU4Health programme 2021-2027 – a vision for a healthier European Union

The EU4Health programme was adopted as a response to the COVID-19 pandemic and to reinforce crisis preparedness in the EU. The pandemic highlighted the fragility of national health systems. The EU4Health programme will bring a contribution to the long-term health challenges by building stronger, more resilient and more accessible health systems.

Health is an investment and, with an initial €5.3 billion budget for the 2021-27 period, reduced to €4.4 billion following the revision of the 2021-2027 MFF, the EU4Health programme is an unparalleled EU financial support in the health area . EU4Health is a clear message that public health is a priority for the EU and it is one of the main instruments to pave the way to a European Health Union .

Established by  Regulation (EU) 2021/522 , EU4Health brings an EU added value and complements the policies of the Member States to pursue four general objective representing the ambitions of the programme and ten specific objectives representing the areas of intervention:

• Health promotion and disease prevention, in particular cancer
• International health initiatives and cooperation
• Prevention, preparedness and response to cross-border health threats
• Complementing national stockpiling of essential crisis-relevant products
• Establishing a reserve of medical, healthcare and support staff
• Ensuring that these products are accessible, available and affordable
• Reinforcing health data, digital tools and services, digital transformation of healthcare
• Enhancing access to healthcare
• Developing and implementing EU health legislation and evidence-based decision making
• Integrated work among national health systems

Objectives of the EU4Health programme

EU4Health and the European Health Union

EU4Health will pave the way to a  European Health Union  by investing in urgent health priorities:

• response to the COVID-19 crisis  and reinforcing the EU’s resilience for  cross-border health threats
• Europe’s Beating Cancer Plan
• Pharmaceutical Strategy for Europe

Other areas, such as health systems’  digitalisation , reducing the number of  antimicrobial-resistant infections  and improving  vaccination  rates will also be boosted.

The EU will expand successful initiatives like the  European Reference Networks  for rare diseases and continue to pursue  international cooperation  on global health threats and challenges.

Work programmes

EU4Health is implemented by annual Work Programmes supporting a broad range of actions that are clustered under four overarching “strands” with a cross-cutting focus on cancer.

• Crisis preparedness
• Health promotion & disease prevention
• Health systems & healthcare workforce

The programme provides funding to eligible entities, health organisations and NGOs from EU countries, or non-EU countries associated to the programme.

Actors involved

A targeted Stakeholders consultation took place from 30/03/2023 to 22/05/2023. A Stakeholders event was organised on 09/06/2023. As a result the following documents were produced:

• EU4Health Stakeholders Consultation – Report
• EU4Health Stakeholders Conference – Report

Many actors are necessary to make EU4Health a reality:

• EU countries are consulted on the priorities and strategic orientations of the programme and work together with the Commission in the ‘EU4Health Steering Group’ to ensure consistency and complementarity with national health policies. They provide their opinion in the EU4Health Programme Committee before the adoption of the annual work programmes.
• Third countries associated to the EU4Health programme participate in the consultation process and observe the work of the EU4Health Steering Group and Programme Committee. They benefit of the funding as any other EU country.
• Stakeholders including representatives of civil society and patients’ associations, academics and organisations of healthcare professionals, provide input on priorities and strategic orientations and on the needs to be addressed through the annual work programme.
• The European Parliament is informed about the progress of the preparatory work and outreach activities with stakeholders.
• The European Commission prepares, adopts and implements the annual work programmes, and monitors and reports on the progress regarding fulfilment of the programme objectives. It may also seek the views of relevant decentralised agencies and of independent experts in the field of health on technical or scientific matters of relevance for the implementation of the programme.
• The Health and Digital Executive Agency ( HaDEA ) implements the programme.

Associated non-EU countries

Norway, Iceland, Ukraine, Moldova, Montenegro and Bosnia and Herzegovina are associated to the EU4Health Programme. 

The association and participation of Norway and Iceland (EFTA countries) to the EU4Health Programme is governed by the Protocol 31 on cooperation in specific fields outside the four freedoms of the Agreement on the European Economic Area (OJ No L 1, 3.1.1994, p. 3). The European Commission signed an association agreement with authorities from Ukraine ,  Moldova , Montenegro and Bosnia and Herzegovina that opens access to EU funding for these countries.

Funding & Tenders

Funding opportunities under the EU4Health Programme are published by the Health and Digital Executive Agency (HaDEA). Please frequently visit HaDEA’s pages on calls for proposals and calls for tenders .

Synergies and complementarities with other funds

Health challenges are cross-cutting by nature. EU4Health works together with other Union programmes, policies, instruments and actions:

• European Social Fund Plus (ESF+) to support vulnerable groups in accessing healthcare
• European Regional and Development Fund to improve regional health infrastructure
• Horizon Europe for health research
• Union Civil Protection Mechanism / rescEU to create stockpiles for emergency medical supplies
• Digital Europe and Connecting Europe Facility for creating the digital infrastructure needed for digital health
• InvestEU Programme
• Single Market Programme
• Recovery and Resilience Facility
• Emergency Support Instrument

Programme monitoring and evaluation

Programme performance and monitoring evaluation framework.

  The EU4Health Programme performance monitoring and evaluation framework (PPMEF) includes the intervention logic, a set of sound indicators to collect data, the monitoring, reporting and evaluation arrangements, and the data, information and knowledge management. The EU4Health PPMEF was developed in line with the monitoring and evaluation provisions of the EU4Health Regulation.

• EU4Health PPMEF

Annual Programme performance monitoring and reporting

The Programme Performance Statement , as part of the Commission’ s strategic planning and programming cycle, is a key tool for annual reporting on the results achieved, challenges encountered and areas for possible improvement. It includes concrete examples of achievements, the rationale and design of the annual work programme, the contribution to the Commission’s general priorities, and the budget performance implementation and outcomes.

• EU4Health PPS published in 2024
• EU4Health PPS published in 2023
• EU4Health PPS published in 2022

Interim and final evaluation

The European Commission will carry out interim and final evaluation of EU4Health Programme. The Commission will publish and communicate the conclusions of both the interim and final evaluations , accompanied by its observations, to the European Parliament, the Council, the European Economic and Social Committee and the Committee of the Regions.

• Interim evaluation updates

More information

• Regulation (EU) 2021/522 establishing a Programme for the Union’s action in the field of health (‘EU4Health Programme’) for the period 2021-2027
• Press release: Commission welcomes entry into force of EU4Health programme
• Questions and Answers: EU4Health Programme 2021-2027
• Press release: Commission welcomes political agreement on EU4Health
• EU4Health proposal (and annexes)
• EU4Health MEMO
• EU4Health factsheet
• Recovery plan for Europe
• MFF 2021-2027 Communication

Previous Health Programmes

Since 2003, EU health programmes have generated knowledge and evidence as a basis for informed policymaking and further research. This includes best practice, tools, and methodologies that benefitted both the public health community and citizens directly (e.g. improving diagnostic tests, supporting EU countries in developing national actions plans on cancer, improving patient care).

• 3 rd EU health Programme (2014-2020)
• 2 nd EU health programme (2008-2013)
• 1 st EU health programme (2003-2007)

Coronavirus research and innovation

EU supported research and innovation projects and initiatives to tackle the spread of coronavirus and preparedness for other outbreaks. 

Overview of research actions to combat COVID-19

The European Commission has been at the forefront of supporting research and innovation and coordinating European and global research efforts, including preparedness for pandemics.

Around €4 billion were invested in infectious diseases research through the 7th Framework Programme and Horizon 2020 from 2007 to 2019 by:

• Supporting key research and innovation projects and the development of new technologies , such as mRNA. BioNTech made use of its mRNA technology to develop and manufacture HIV vaccine candidates in the EAVI2020 project, which started in 2015.
• Investing in developing clinical networks and research infrastructures to ensure preparedness to deliver clinical research. Projects such as COMBACTE and PREPARE laid the groundwork for EU-funded projects in the area of preparedness to outbreaks, including new ways of designing and implementing efficient clinical trials which were key to understand and tackle the COVID-19 pandemic.
• Boosting epidemiology research and modelling and social science to develop better monitoring systems and understand the social causes and consequences of outbreaks.

As a response to the COVID-19 pandemic, the Commission launched several  special actions for coronavirus research from Horizon 2020 and Horizon Europe , as part of a €1 billion  pledge for coronavirus research.

• On 30 January 2020 , the European Commission launched its first emergency call on Coronavirus research through which €48.2 million were awarded to 18 research projects .
• On 19 May 2020 , the Commission launched a second emergency call , through which €128 million were awarded to 24 research projects .
• Projects funded via these two calls encompass the full spectrum of research and innovation to respond to the threat and better prepare for future outbreaks, from basic research, modelling, digital tools, epidemiology, the development of diagnostics, treatments and vaccines, to the understanding of behaviour and socio-economic effects during the outbreak, as well as the infrastructures and resources that enable all this research.

Making use of the full range of instruments

The full range of research and innovation instruments under the Framework Programmes was swiftly mobilised to deliver the necessary evidence and tools across the full research and innovation value chain: European Research Council, collaborative research, public-public and public-private partnerships ( European and Developing Countries Clinical Trials Partnership and Innovative Medicines Initiative  /  Innovative Health Initiative ), European Innovation Council and the European Investment Bank .

With a financial support of €100 million, the European Investment Bank was instrumental in helping BioNTech to use the mRNA technology for the development of a COVID-19 vaccine candidate. The EC-mediated advance purchase agreement further enabled the manufacturing of the BioNTech-Pfizer vaccine, which was the first to receive marketing authorisation in the EU.

HERA Incubator call 

In addition, the Commission announced the HERA Incubator call for urgent research into coronavirus variants on 15 April 2021 , with €120 million . 12 projects are funded under this call, which are addressing the four topics of the emergency request for expressions of interest:

• Clinical trials for therapeutics and vaccines to boost COVID-19 prevention and treatment and further inform public health policy and clinical management.
• Cohorts united against COVID-19 variants of concern supporting activities that are enabling or contributing to the development of large scale, COVID-19 cohorts and networks worldwide, including beyond Europe’s borders, forging links with European initiatives as a global response to the pandemic.
• FAIR and open data sharing in support to European preparedness for COVID-19 and other infectious diseases, to further develop and integrate platforms for the sharing of relevant research resources.
• Research infrastructure services for rapid research responses to COVID-19 and other infectious disease epidemics, to set up and provide access to a comprehensive portfolio of relevant services.

Trial networks

To ensure that the most promising medical countermeasures to fight the COVID-19 pandemic were developed, the European Commission established two European trial networks that enable the implementation of large-scale multi-centre clinical trials: a therapeutics trial network, and a vaccine trials network.

• The network on COVID-19 therapeutic trials consists of three EU-funded trials, covering hospitalised and intensive care patients. The EU SolidAct trial ; the DisCoVeRy trial and the REMAP-CAP trial. A fourth adaptive platform trial looking for treatments in a primary care population is being set up under the ECRAID-PRIME project, which was funded under the HERA incubator call. These projects share a joint coordination module to ensure optimal coordination of trials in the EU and abroad and provides a single-entry point for new study arms in the European COVID-19 adaptive platform trials. The coordination module is composed of a Trial Coordination Board (TCB), a Joint Access Advisory Mechanism (JAAM) and an Adaptive Platform Trial Toolbox.

The therapeutic trials have actively contributed to informing clinical patient management. A key result from the REMAP-CAP trial concerned the use of Tocilizumab and Sarilumab, monoclonal antibodies normally used for rheumatoid arthritis, and which are now routinely integrated in the management of severely ill COVID-19 patients. The DisCoVeRy trial contributed to the evidence related to the absence of effect of treatment with Hydroxychloroquine, Lopinavir and Interferon.

• The European vaccine trial network ( VACCELERATE ) acts as a single-entry point for vaccine developers that are interested in doing vaccine trials in Europe. As of 1 September 2023, it gathers 490 sites in 39 countries, and keeps a registry for volunteers – including children – who are interested in participating in vaccine trials. VACCELERATE currently implements three trials assessing the immune response to the COVID-19 vaccines in both adults and children.
• Both networks (vaccines and therapeutics) are key contributors to the consultation of the World Health Organization on the implementation of the Resolution 75.8 passed by the World Health Assembly in May 2022 on ‘Strengthening clinical trials to provide high-quality evidence on health interventions and to improve research quality and coordination’.

COVID-19 Data Portal

Moreover, the COVID-19 Data Portal was launched in April 2020 to bring together relevant datasets for sharing and analysis in an effort to accelerate coronavirus research. It enables researchers to upload, access and analyse COVID-19 related reference data and specialist datasets as part of the wider European COVID-19 Data Platform, a priority pilot of the European Open Science Cloud.

Building on the success of this platform, the BeYond-COVID ( BY-COVID ) project was awarded with €12 million funding from Horizon Europe to provide comprehensive open data on SARS-CoV-2 and other infectious diseases across scientific, medical, public health and policy domains.

In the context of BY-COVID, the platform now integrates Social Sciences and Humanities COVID-related data from the Consortium of European Social Science Data Archives (CESSDA) ERIC . In addition, the platform is being repurposed and already accepting monkeypox viral data, illustrating that it can become a blueprint for other pathogens and diseases.

Research on the post COVID-19 condition (also known as “long COVID”)

The Commission is funding research to understand and tackle long COVID from  early on in the COVID-19 pandemic in 2020.

Around €66 million were invested to support large cohort studies on COVID-19 that are following populations from around the world during longer periods of time to help determine long-term consequences and symptoms of COVID-19 infections. These include the Horizon 2020 project ORCHESTRA (€26 million) from the first Expression of Interest call in January 2020, and also four Horizon Europe projects VERDI , COVICIS , EU-CARE and END-VOC funded from the HERA Incubator call in 2021 (around €10 million per project).

To ensure and strengthen effective collaboration and networking between the EU-funded COVID-19 cohort projects, the Commission established a Cohorts Coordination Board. The Cohorts Coordination Board brings together all relevant projects to work together on specific topics such as data standards, data harmonisation and long-term syndromes of COVID-19 patients. A dedicated long-COVID Working Group has been set up under the Cohorts Coordination Board to share findings related to long COVID and to provide more robust evidence needed to better characterise long COVID and facilitate its diagnosis, symptoms’ management and potential therapeutic approaches.

Additionally, the DRAGON project (€11.5 million) funded by IMI2 in October 2020 launched a global study on long COVID.

More recently, under the 2021 Horizon Europe call, “Personalised medicine and infectious diseases: understanding the individual host response to viruses (e.g. SARS-CoV-2)” , the Commission funded six projects which conduct research activities on understanding, diagnosis and potential treatment of long COVID: LONG COVID ; NEUROCOV ; HERVCOV ; UNDINE ; REACT and EPIVINF . These projects started between June-September 2022 and receive a total budget of €42.3 million.

Pandemic preparedness partnership

A European partnership for pandemic preparedness is under development, to improve EU’s preparedness to predict and respond to emerging infectious health threats. The partnership will ensure better coordination of funding for research and innovation at EU, national and regional level towards common objectives and an agreed Strategic Research and Innovation Agenda.

Preparatory work on the Pandemic Preparedness Partnership is being done via the BE READY project, which is a coordination and support action funded under Horizon Europe. BE READY started its work in September 2022 and brings together 13 Member States, Norway and the United Kingdom. The main task of BE READY is to prepare the partnership proposal as well as a strategic innovation and research agenda on pandemic preparedness.

COVID-19 Pandemic timeline

See below the key points of the EU response to the pandemic. For the full coverage you can visit the Archived Coronavirus website .

World Health Organization (WHO) declares the new coronavirus outbreak a public health emergency of international concern.

First emergency call on Coronavirus research is launched by the Commission, through which €48.2 million were awarded to 18 research projects.

Second emergency call on Coronavirus research is launched by the Commission, through which 24 research projects where funded.

HERA incubator call is launched for urgent research into coronavirus variants.

• 21 JULY 2021
• 29 MARCH 2021
• 29 JANUARY 2021
• 25 JUNE 2020
• 10 JUNE 2020

Follow the latest progress and get involved.

• European Commission
• EU Science and Innovation
• #coronavirus
• Other social networks
• News article

The Expert Group warns of further set-backs to gender equality in R&I if the impact of the COVID-19 pandemic remains unaddressed

• 23 May 2022

Research and innovation - News alert

20 research projects selected for funding to support the EU Mission on Cancer

Background information.

The EU Cancer Mission aims to optimise the diagnosis and treatment and support the quality of life of cancer patients. It also focuses on preventing this life-threatening disease from affecting millions in the EU.

On 22 May 2022, HaDEA launched 1 call for proposals with 5 topics with a total funding of €126 million under the Horizon Europe programme to contribute to the swift implementation of the EU Cancer Mission. 20 proposals were shortlisted, resulting in 20 new collaborative projects. 

Share this page

Supporting innovation

This content applies to human and veterinary medicines.

EMA and its regulatory partners foster research and the uptake of innovative products , methods and technologies in the development of medicines, in line with:

• European medicines agencies network strategy to 2025
• EMA Regulatory Science Strategy to 2025

Advice mechanisms

Innovation task force (itf) briefing meetings.

Innovation Task Force (ITF) briefing meetings provide developers a forum for early dialogue   on innovative medicines with EMA.

They assist developers in deciding on next steps in their development programmes .

ITF briefing meetings:

• cover regulatory, technical and scientific concerns arising from innovative medicines, technologies and methodologies;
• should held at much earlier stage of the development than the scientific advice;
• enable informal exchange of information and guidance in the development process, complementing existing formal EMA procedures;
• are aimed at all types of developer, including academic researchers, micro, small and medium-sized enterprises (SMEs) and large pharmaceutical companies.

These meetings are free-of-charge and held virtually .

Areas of special support:

• Artificial intelligence (AI)
• Advanced therapy medicinal products (ATMPs)
• Implementing the replacement, reduction and refinement of animal use (3Rs) principle
• Antimicrobial resistance (AMR)

To apply for an ITF briefing meeting,  complete the request form below and email it to: 

• [email protected]  - for human medicines
• [email protected]  - for veterinary medicines

Innovation Task Force (ITF) briefing meeting request form

English (EN) (144.66 KB - DOCX)

Innovation Task Force (ITF) briefing meeting - Briefing document template

English (EN) (130.72 KB - DOCX)

Innovation Task Force (ITF) briefing meeting - Instructions on how to apply

English (EN) (523.33 KB - PDF)

Portfolio and technology meetings (updated)

Pharmaceutical companies with large medicinal product portfolios can apply to attend informal meetings with EMA to:

• identify any issues impacting the progress of product portfolios and assist successful development;
• capture innovative and disruptive technologies;
• anticipate the scientific and regulatory expertise needed to assess future applications.

These meetings are free-of-charge and held virtually .

Applications open

Applications are open for the meetings to be held in Q1 and Q2 2025.

Apply by 15 November 2024 via the application form available below: 

• Portfolio and technology meetings application form

EMA will advise applicants on the next steps by the end of December 2024.

EMA will publish a call for Q3 and Q4 2025 meetings in Q1 2025.

Contact: 

• [email protected]

Regulatory support for micro, small and medium-sized enterprises (SMEs)

EMA provides incentives   and support for micro, small and medium-sized enterprises (SMEs) that are developing medicines for human or veterinary use, to promote innovation and the development of new medicines.

More information:

• Support to SMEs

Regulatory guidance for academics

EMA maintains a strong working relationship with European academics and researchers . This helps EMA prepare for future challenges and opportunities presented by advances in science and technology. 

EMA engages with academia, learned societies and research groups and offers support for academic developers .

More information: 

• Qualification of novel methodologies for medicine development

The European Medicines Agency offers scientific advice to support the qualification of innovative development methods for a specific intended use in the context of research and development into pharmaceuticals.

• Scientific advice

The European Medicines Agency can provide medicine developers advice on the most appropriate way to generate robust evidence on a medicine's benefits and risks.

EMA provides scientific advice to support the timely and sound development of high-quality, effective and safe medicines, for the benefit of patients. 

• Scientific advice and protocol assistance (human medicines)
• Scientific advice (veterinary medicines)
• Quality Innovation Group

The Quality Innovation Group (QIG) supports the translation of innovative approaches to the design , manufacture and quality control of medicines, to bring new therapies and help improve the supply of existing medicines to patients.

Innovation initiatives

• EU-Innovation Network (EU-IN)

The EU Innovation Network (EU-IN) is a working group that helps the European medicines regulatory network facilitate the development of innovative medicines and associated technologies in the EU.

• Regulatory science research needs

EMA has identified around one hundred topics where research is needed to address knowledge gaps in regulatory science.

Research in these areas can support medicine development and evaluation, ultimately helping patients in the EU access  innovative medicines  that address their needs.

• Accelerating Clinical Trials in the EU (ACT EU)

The Accelerating Clinical Trials in the EU (ACT EU) initiative aims to develop the EU further as a competitive centre for innovative clinical research .

The European Commission, EMA and Heads of Medicines Agencies (HMA) run ACT EU together.

The EU Health Programme, EU4Health, is a research funding programme offered by the EU.

It focuses on strengthening healthcare and promotes innovation .

Priorities areas include health promotion and disease prevention, digital transformation and healthcare staff.

EC funding programmes

EMA and the European Commission provide support to medicine developers applying for funding under the European Union’s  Horizon Europe programme in the area of health .

• EU funding programmes
• European Partnerships

European Partnerships such as the Innovative Health Initiative (IHI), ERA4Health, One Health Antimicrobial Resistance, Personalised Medicines Partnership and Rare Diseases Partnership fund research and innovation in health and interventions.

• Innovative Health Initiative (IHI)
• EU Action on Antimicrobial Resistance

Key innovation topics

Artificial intelligence.

EMA's scientific activities on artificial intelligence (AI) help medicine developers prepare marketing authorisation applications for human medicines.

• Scientific guidelines: Artificial intelligence (AI)
• Big data: Artificial intelligence (AI)

Advanced therapy medicinal products

Advanced therapy medicinal products (ATMPs) are medicines for human use that are based on genes, tissues or cells. They offer groundbreaking new opportunities for the treatment of disease and injury.

• Advanced therapy medicinal products: Overview
• Ethical use of animals in medicine testing

EMA supports the implementation of the so-called 3Rs principles - replace, reduce and refine - for the ethical use of animals in medicine testing across the European Union (EU).

These principles encourage alternatives to the use of animals in the testing of medicines while safeguarding scientific quality and improving animal welfare where the use of animals cannot be avoided.

• Antimicrobial resistance

The emerging and steady increase of microbes that are resistant to antimicrobial treatments has become a global public health concern that threatens the effective treatment of infectious diseases.

Combatting this threat, particularly resistance to antibiotics, is a high priority for EMA and the European medicines regulatory network.

Digital technologies for human medicines

The European medicines regulatory network provides comprehensive advice on digital technologies to applicants, a rapidly evolving regulatory field.

Novel therapies and technologies for veterinary medicines

EMA's Novel Therapies and Technologies Working Party provides recommendations to the Committee for Veterinary Medicinal Products (CVMP) on all matters relating to veterinary novel therapies and technologies .

• Novel Therapies and Technologies Working Party
• Innovation in veterinary medicines

Genome editing

EMA's Regulatory science strategy  and the European medicines agencies network strategy set out recommendations in the field of genome editing technologies. 

Genome editing EU-IN Horizon Scanning Report

English (EN) (374.11 KB - PDF)

Related content

• European medicines agencies network strategy
• Regulatory science strategy

External content

• Innovative Health Initiative
• Regulatory and procedural guidance
• Research and development

Share this page